Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) – Investment analysts at SunTrust Banks issued their FY2022 EPS estimates for shares of Galmed Pharmaceuticals in a note issued to investors on Thursday. SunTrust Banks analyst E. Nash expects that the biopharmaceutical company will post earnings of $0.03 per share for the year.
A number of other research firms have also recently weighed in on GLMD. Zacks Investment Research upgraded Galmed Pharmaceuticals from a “hold” rating to a “buy” rating and set a $13.00 price target on the stock in a report on Wednesday, January 10th. ValuEngine upgraded Galmed Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. Maxim Group set a $14.00 price target on Galmed Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, January 3rd. HC Wainwright upped their price target on Galmed Pharmaceuticals from $18.00 to $24.00 and gave the stock a “buy” rating in a report on Monday, February 12th. Finally, Roth Capital began coverage on Galmed Pharmaceuticals in a report on Wednesday, November 15th. They issued a “buy” rating and a $32.00 price target on the stock. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $20.40.
A number of hedge funds have recently bought and sold shares of GLMD. Deutsche Bank AG purchased a new stake in Galmed Pharmaceuticals in the 4th quarter valued at approximately $246,000. Renaissance Technologies LLC purchased a new stake in Galmed Pharmaceuticals in the 4th quarter valued at approximately $345,000. J. Goldman & Co LP purchased a new stake in Galmed Pharmaceuticals in the 4th quarter valued at approximately $569,000. Sphera Funds Management LTD. purchased a new stake in Galmed Pharmaceuticals in the 4th quarter valued at approximately $2,164,000. Finally, Park West Asset Management LLC lifted its stake in Galmed Pharmaceuticals by 4.4% in the 4th quarter. Park West Asset Management LLC now owns 292,847 shares of the biopharmaceutical company’s stock valued at $2,679,000 after buying an additional 12,347 shares in the last quarter. 11.90% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: This piece of content was first published by Community Financial News and is the property of of Community Financial News. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright laws. The legal version of this piece of content can be read at https://www.com-unik.info/2018/02/20/galmed-pharmaceuticals-ltd-expected-to-earn-fy2022-earnings-of-0-03-per-share-glmd.html.
About Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol.
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.